Artivion (NYSE:AORT) Earns Buy Rating from Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They presently have a $34.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 17.04% from the stock’s previous close.

AORT has been the subject of a number of other research reports. JMP Securities assumed coverage on shares of Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price for the company. Stifel Nicolaus increased their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Oppenheimer raised their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $31.80.

Artivion Stock Down 2.1 %

NYSE AORT traded down $0.61 during trading hours on Monday, hitting $29.05. 157,967 shares of the company were exchanged, compared to its average volume of 224,385. Artivion has a 52-week low of $16.48 and a 52-week high of $30.10. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -1,458.50 and a beta of 1.75. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a 50 day moving average of $27.39 and a two-hundred day moving average of $26.03.

Insiders Place Their Bets

In other news, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. The trade was a 18.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP bought a new position in shares of Artivion during the 3rd quarter worth about $565,000. Sio Capital Management LLC bought a new position in Artivion during the third quarter valued at $3,226,000. First Eagle Investment Management LLC raised its stake in Artivion by 4.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after acquiring an additional 27,906 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after purchasing an additional 125,668 shares in the last quarter. Finally, Quest Partners LLC grew its stake in Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock valued at $661,000 after buying an additional 24,817 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.